KBC Group
AEGR

KBC Group’s Aegerion Pharmaceuticals AEGR Stock Holding History

KBC Group’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2,003
Closed -$64K – 1364
2014
Q2 		$64K Sell
2,003
-199,205
-99% -$7.42M ﹤0.01% 1254
2014
Q1 		$9.29M Buy
201,208
+17,716
+10% +$1.04M 0.15% 180
2013
Q4 		$13M Buy
+183,492
New +$14M 0.2% 130

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KBC Group's AEGR Position: Q3 2014 in Review

KBC Group sold out of Aegerion Pharmaceuticals (AEGR) in Q3 2014, closing a stake of 2,003 shares — an estimated $64K sold.

KBC Group first reported a position in AEGR in Q4 2013 and held it in 3 quarters. The position peaked at $13M in Q4 2013. 131 funds tracked by Wall St. Rank hold AEGR as of Q3 2014.

  • KBC Group reported no remaining Aegerion Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • KBC Group sold 2,003 Aegerion Pharmaceuticals shares in Q3 2014, an estimated $64K.
  • KBC Group first reported a position in Aegerion Pharmaceuticals in Q4 2013 and held it in 3 quarters.
  • KBC Group's Aegerion Pharmaceuticals position peaked at $13M in Q4 2013.
  • 131 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q3 2014.

Based on KBC Group's 13F filing for Q3 2014, filed 16 Oct 2014.